WO2024028896A1 - A topical spray based on beta caryophylene for the management of pain and inflammation - Google Patents

A topical spray based on beta caryophylene for the management of pain and inflammation Download PDF

Info

Publication number
WO2024028896A1
WO2024028896A1 PCT/IN2023/050741 IN2023050741W WO2024028896A1 WO 2024028896 A1 WO2024028896 A1 WO 2024028896A1 IN 2023050741 W IN2023050741 W IN 2023050741W WO 2024028896 A1 WO2024028896 A1 WO 2024028896A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mixture
caryophyllene
minutes
pain
Prior art date
Application number
PCT/IN2023/050741
Other languages
French (fr)
Inventor
Pirthi Pal SINGH PARTAP SINGH
Anubhav GOYAL
Rajesh Gupta
Original Assignee
Pontika Aerotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontika Aerotech Ltd filed Critical Pontika Aerotech Ltd
Publication of WO2024028896A1 publication Critical patent/WO2024028896A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention generally relates to pharmaceutical sciences. Specifically, the present invention is related to a topical spray composition comprising isolated P-caryophyllene, benzalkonium chloride, propellant, pharmaceutically acceptable excipients, and optionally an additional active component for the management of pain, inflammation, and other pain related disorders. Also, the present invention provides a method for producing the same and uses thereof.
  • Beta-Caryophyllene chemically represented as trans-(lR, 9S)-8-Methylene- 4,l l,l l-trimethylbicyclo-7.2.0 undec-4-ene or lR-(lR4E.9S)-4,l l,l l-trimethyl-8-methylene- bicyclo7.2.0 undec-4-ene) is a natural bicyclic sesquiterpene compound found in spice blends, citrus flavors, Soaps, detergents, creams and lotions, and also in a variety of food products and beverages.
  • trans-caryophyllene (E)-BCP) mixed with small amounts of its isomers, (Z)-P-caryophyllene (iso-caryophyllene) and a-humulene (a-caryophyllene), as well as its oxidation derivative — P-caryophyllene oxide (BCPO).
  • BCP mainly stands for (E)-BCP or the natural mixture of BCP isomers.
  • P-caryophyllene is the first known dietary cannabinoid, a common component of food that has GRAS (Generally Recognized as Safe) status and approved by FDA as well as by the European Food Safety Authority (EFSA) with identification number FL no: 01.007 for food use.
  • GRAS Generally Recognized as Safe
  • EFSA European Food Safety Authority
  • BCP is a colorless to slightly buttery liquid with a light clove-like fragrance. It is soluble in ether and ethanol, insoluble in water.
  • the chemical structure of P-caryophyllene is as follows:
  • BCP is one of the major active components of essential oils derived from large number of spice and food plants. According to Essential Oil Database, BCP as a plant volatile compound is commonly found in basil (Ocimum spp.), cinnamon (Cinnamomum spp.), black pepper (Piper nigrum L.), cloves (Syzygium aromaticum), cannabis (Cannabis sativa L.), lavender (Lavandula angustifolia), oregano (Origanum vulgare L.), rosemary (Rosmarinus officinalis), hops (Humulus lupulus), and copaiba (Copaifera langsdorffii).
  • P-caryophyllene has several biological effects including anti-inflammatory, anticarcinogenic, antimicrobial, antioxidative, and analgesic activities.
  • P-caryophyllene is the primary sesquiterpene contributing to the spiciness of black pepper.
  • P-caryophyllene belongs to a class of cannabinoids (CBs), specifically phytocannabinoids (pCBs), which were identified as plant derivatives of Cannabis sativa L.
  • Natural and synthetic cannabinoids activate the cannabinoid receptors CB1 and CB2, however P- caryophyllene activates exclusively CB2 and exhibits no affinity to CB1.
  • Klaudyna et. al. [Cancer Medicine 2016; 5( 10):3007-3017] in a study reported through quantitative radioligand binding experiments that P-caryophyllene displays insensibly higher biding affinity to CB2 and do not bind to CB 1. This implies that P-caryophyllene action is devoid of psychoactive side effects associated with CB 1 activation and suggests its potential use in medicine.
  • Pain is a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors — peripheral neurons responding to pain stimuli. Pain is classified as acute or chronic, according to its duration. Short-lived pain, generally associated with tissue damage or painful stimuli (e.g. the pain associated with a slight burn, a cut etc.), is defined "acute pain", and has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
  • Pain which persists beyond the time necessary for resolution of an acute condition is defined as "chronic pain”. Pain is a serious social burden; it affects quality of life and leads to economic loss for patients as well as health services. It has been estimated that 20% of adults suffer from pain globally and around 10% of population worldwide suffers from long lasting pain [Goldberg and McGee BMC Public Health 2011, 11:770].
  • various substances are used, generally of a synthetic nature such as non-steroid anti-inflammatory drugs, opioids, etc., which induce analgesia, i.e., reduction in the sensation of pain.
  • the treatments may be necessary for long periods, sometimes even for life. This leads to overuse of synthetic or semisynthetic pain killers such as opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). Prolonged consumption of these medicines may cause serious side effects leading to health complications as well as drug tolerance for analgesic effect and addiction.
  • synthetic drugs natural products with strong analgesic activities and low side effects are sought.
  • cannabinoid receptors have been extensively studied as mediators of analgesia and thus potential targets for treatment of acute and neuropathic pain and inflammation. Activation of those receptors by endo- and exogenous ligands may inhibit pain responses, therefore CBs are considered as substances with high analgesic activities.
  • THC tetrahydrocannabinol
  • P-caryophyllene has potential as an efficient natural analgesic without any side effects like psychoactivity, dependence and sedation.
  • P-caryophyllene based analgesic compositions have been reported.
  • US20080280996 provides a composition comprising caryophyllenes including P-caryophyllene for the treatment of inflammatory conditions and inflammatory pain.
  • AU2020412501 provides a composition comprising terpenes including P-caryophyllene for the treatment of pain and anxiety.
  • P-caryophyllene has extremely low solubility in biological fluids leading to low bioavailability of P-caryophyllene and insufficient analgesic effect. This limits exploitation of this readily available, natural, and safe analgesic to its fullest potential.
  • the present invention provides a topical spray composition for the management of pain, inflammation, and related disorders.
  • the said composition comprises 2% w/w to 98% w/w of an isolated P-caryophyllene, 0.01% w/w to 3.5% w/w of benzalkonium chloride, 10% w/w to 70% w/w of a propellant, 30% w/w to 70% w/w of at least one excipient, and optionally 0.05% w/w to 40% w/w of an additional active component.
  • the said composition is in form of a topical spray which can be sprayed on the skin to obtain relief from pain and inflammation within 2 minutes and the analgesic effect imparted by the said topical spray composition sustains for about 18 hours.
  • the topical spray composition provided herein has enhanced absorption on the skin.
  • the present invention also provides simple process for the preparation of said topical spray composition, method for the management of pain, inflammation, and related disorders by spraying said composition on the skin of a subject, and uses of said composition in the management of pain, inflammation, and related disorders.
  • the topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
  • the topical spray composition provided herein has analgesic effect better than the standard diclofenac -based analgesic sprays and has no side-effects like psycho-activity, dependence, and sedation.
  • Figure 1 illustrates onset time through evaluation of response latency of the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
  • Figure 2 illustrates duration of analgesic effect through evaluation of % protection against acute pain imparted by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac ( 1 % w/w of Diclofenac sodium).
  • Figure 3 illustrates Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and McGill pain scores from baseline to Post study in both the groups by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
  • VAS Visual Analogue Scale
  • WOMAC Osteoarthritis Index
  • TruMove or “TruMove spray” used herein refers to a series of test products based on the topical spray composition provided herein.
  • a topical spray composition for the management of pain, inflammation, and related disorders comprising: a therapeutically effective amount of an isolated P-caryophyllene; a pharmaceutically acceptable amount of a benzalkonium chloride; a pharmaceutically acceptable amount of a propellant; a pharmaceutically acceptable excipient; and optionally an additional active component.
  • P-caryophyllene or “beta-caryophyllene” or “BCP” or “beta caryophyllene” used herein refers to a compound represented by the following formula:
  • isolated P-caryophyllene refers to P-caryophyllene available commercially as mixture of oils, P-caryophyllene extracted from natural plants by conventional methods, or P- caryophyllene prepared by synthetic routes.
  • the topical spray composition provided herein comprises a therapeutically effective amount of isolated P-caryophyllene.
  • the topical spray composition provided herein comprises about 2% w/w to 98% w/w of isolated P-caryophyllene.
  • the isolated P-caryophyllene present in the topical spray composition is in form of oil comprising about 70% w/w to 100% w/w of P-caryophyllene.
  • the isolated P-caryophyllene present in the topical spray composition is in form of oil extracted from a group of plants comprising basil ⁇ Ocimum spp.), cinnamon ⁇ Cinnamomum spp.), black pepper Piper nigrum L.), cloves ⁇ Syzygium aromaticuni), cannabis Cannabis sativa L.), lavender ⁇ Lavandula angustifolia), oregano ⁇ Origanum vulgare L.), rosemary ⁇ Rosmarinus officinalis), hops ⁇ Humulus lupulus), and copaiba ⁇ Copaifera langsdorffii).
  • the isolated P-caryophyllene is extracted from cloves.
  • the isolated P-caryophyllene is extracted from clove leaves.
  • therapeutically effective amount refers to the amount of the active ingredient in a composition which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
  • the therapeutically effective amount of isolated P-caryophyllene in the topical spray composition disclosed herein is in a range of about 20mg to 980mg.
  • the therapeutically effective amount of isolated P- caryophyllene is in a range of about lOmg to 70mg.
  • the term “about” used herein refers to the referenced numeric indication plus or minus 10% of that referenced numeric indication.
  • Benzalkonium Chloride or “BAC” used herein refers to a compound represented by the following formula: wherein n is equal to 8, 10, 12, 14, 16 and 18.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable amount of benzalkonium chloride.
  • the topical spray composition provided herein comprises benzalkonium chloride in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
  • the topical spray composition provided herein has enhanced skin absorption due to incorporation of benzalkonium chloride.
  • the enhanced absorption of the composition disclosed herein is increasing the bioavailability of P-caryophyllene and enabling sufficient analgesic effect in highly safe manner through activation of only CB2 receptor.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipient refers to a compound or ingredient that is compatible with the other ingredients in a pharmaceutical composition and not injurious to an intended subject when administered in normal or therapeutically effective amounts.
  • an “intended subject” includes animals and/or humans.
  • patient and “subject” may be used interchangeably.
  • the topical spray composition provided herein comprises an excipient in a concentration range of 30% w/w to 70% w/w of the composition.
  • the topical spray composition provided herein comprises an excipient selected from a group of commonly used excipients in topical spray compositions comprising emulsifier, preservative, penetration enhancer, emollient, stabilizing agent, solvent, fragrance, and a combination thereof.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable emulsifier selected from a group of commonly used emulsifiers comprising non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, anionic surface active agent e.g., alkyl phosphoric acid ester, alkyl sulfate ester, soap, polyoxyethylene alkyl phosphate acid ester, polyoxyethylene alkyl sulfate, and a combination thereof.
  • non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid este
  • the topical spray composition provided herein comprises a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
  • a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable preservative selected from a group of commonly used preservatives comprising benzalkonium chloride, diazolidinyl urea; iodopropnyl butylcarbamate; vitamin E (alpha- tocopherol) and its derivatives including vitamin E acetate (alpha-tocopherol acetate); vitamin C (ascorbic acid); butylated hydroxytoluene (BHT); butylated hydroxyanisole (BHA); esters of p-hydroxy benzoic acid such as methylparaben (p-hydroxybenzoic acid methyl ester), ethylparaben (p- hydroxybenzoic acid ethyl ester), propylparaben (p-hydroxybenzoic acid n- propyl ester), and butylparaben (p-hydroxybenzoic acid n-butyl ester), and a combination thereof.
  • a pharmaceutically acceptable preservative selected
  • the topical spray composition provided herein comprises a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicaprylyl carbonate, C12-C15 alkyl benzoate, isopropyl isononate, sucrose palmitate, sucrose oleate, isostearyl lactate, glyceryl behenate, triglycerol-4 isostearate, lauryl pirrolidone carboxylic acid, pantenyl triacetate, and a combination thereof.
  • a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicap
  • the topical spray composition provided herein comprises a pharmaceutically acceptable solvent selected from a group of commonly used solvents comprising ketones such as acetone, diacetone alcohol, dihydroxyacetone, ethyl butyl Valero lactone, methyl ethyl ketone etc., aliphatic or aromatic alcohols such as methanol, ethanol, propanol, benzyl alcohol, butyl alcohol, t-butyl alcohol, butylene glycol, diethylene glycol, abietyl alcohol, propylene carbonate, hexyl alcohol, isopropanol etc., glycol ethers such as butoxy ethanol, butoxypropanol, 3-methyl-3-methoxy-butanol, methoxypropanol etc., esters such as butyl acetate, ethyl acetate, 1 -methoxy-2-propanol acetate etc., benzoates, siloxanes, cyclic silicones, and
  • the topical spray composition provided herein comprises ethanol as solvent.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable fragrance or flavouring agent selected from a group of commonly used fragrances or flavouring agents selected from a group comprising natural oils, synthetic oils, alcohols, aldehydes, ketones, esters, lactones, hydrocarbons, and a combination thereof.
  • the topical spray composition provided herein comprises a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic liquids, and deep eutectic solvents, and a combination thereof.
  • a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic
  • the topical spray composition provided herein comprises a propellant.
  • the propellant used in the topical spray provided herein can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure in range of 20 pounds per square inch gauge (psig) to 130 pounds per square inch gauge (psig).
  • the topical spray composition provided herein comprises a propellant in a concentration range of 10% w/w to 70% w/w of the composition.
  • the topical spray composition provided herein comprises a propellant selected from a group comprising nitrogen, carbon dioxide, hydrocarbons, and a combination thereof.
  • the topical spray composition provided herein comprises a propellant selected from a group comprising LPG, propane, butane, isobutane, dimethylether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
  • the topical spray composition provided herein comprises an optional additional active component.
  • active component refers to a component which has some already known biological activity.
  • the said component can be an individual biologically active compound or a mixture of biologically active compounds.
  • the biologically active compounds may or may not have analgesic activity.
  • the said component can be of natural origin, a natural identical of a natural compound, or a semi-synthetic derivative of a natural compound.
  • the topical spray composition provided herein comprises optionally an additional active component in a concentration range of 0.05% w/w to 40% w/w of the composition.
  • the topical spray composition provided herein comprises optionally an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
  • an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil
  • the topical spray composition provided herein is applied topically on the skin once a day to four times a day to a patient or subject.
  • the topical spray composition provided herein has an onset time between 2 minutes to 15 minutes.
  • onset time refers to the period of time between the topical application of the topical dosage form comprising the composition of the present invention and the release of the active ingredient thereof.
  • the topical spray composition provided herein has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
  • the topical spray composition provided herein is used for the management of pain, inflammation, and related disorders.
  • pain or inflammation refers to a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors, the peripheral neurons responding to pain stimuli.
  • the term "pain” or “inflammation” includes acute pain or inflammation as well as chronic pain or inflammation.
  • the short-lived acute pain or inflammation is generally associated with tissue damage or painful stimuli (e.g., the pain associated with a slight burn, a cut etc.).
  • Acute pain or inflammation has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
  • pain or inflammation which persists beyond the time necessary for resolution of an acute condition is defined as chronic pain or inflammation.
  • the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising arthralgia, backache, neuralgia, ischialgia, fibromyalgia, musculo-skeletal pain, pelvic pain, and related disorders.
  • the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising atopic dermatitis, contact dermatitis, allergic dermatitis, pruritic dermatitis, solar (UVB -induced) dermatitis, chemical-induced dermatitis, bacterial and viral skin inflammation, acne, psoriasis, and related disorders.
  • a process for the preparation of topical spray composition comprises steps of, preparing a mixture of Mentha arvensis crystals and a solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture; adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture; adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture; preparing a solution of benzalkonium chloride in a solvent, adding the solution into
  • the topical spray composition provided herein may be filled in an aluminium aerosol container without a propellant to obtain a topical spray.
  • ethanol is used as solvent.
  • a method for the management of pain, inflammation, and related disorders by applying on the skin of a subject the topical spray composition provided by the present invention.
  • a topical spray composition provided by the present invention in the management of pain, inflammation, and related disorders.
  • the topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
  • the topical spray composition provided herein has analgesic effect better than diclofenac based topical analgesic sprays. Due to presence of natural analgesic P-caryophyllene as major component, the topical spray composition provided herein is extremely safe and free from adverse reactions like application site dermatitis which is generally experienced by patients in long term usage of diclofenac based topical sprays. The safety associated with the topical spray composition provided herein will lead to better patient compliance.
  • the topical spray composition provided herein has no side-effects like psycho-activity, dependence, sedation etc., and can be advantageously used as a safe alternative to natural cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
  • cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
  • a mixture of Mentha arvensis crystals and ethanol is prepared by stirring Mentha arvensis crystals and ethanol at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 20 minutes.
  • Lavang Synzygium aromaticum
  • Gandhapura Gaultheria fragrantissima
  • Lavang Synzygium aromaticum
  • Fl. Bud Oil Lavang (Syzygium aromaticum)
  • Sarala Pieri
  • Ht.Wd. Oil Nilgiri (Eucalyptus globulus) Lf. Oil
  • Dalchini Cinnamomum zeylanicum
  • Oil are added and stirred at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes. Thereafter, isopropyl myristate and polysorbate 80 (Tween 80) are added into the mixture so obtained followed by stirring at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes.
  • An ethanolic solution of benzalkonium chloride is prepared in a separate container by stirring ethanol and benzalkonium chloride at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes.
  • the ethanolic solution of benzalkonium chloride so prepared is then added into the mixture in main manufacturing vessel and stirred for 5 minutes at a speed in range of 10 rpm to 500 rpm.
  • the mixture so obtained is then diluted with ethanol, stirred, and filtered to obtain a concentrate.
  • the concentrate is then filled inside a spray bottle with a propellant to obtain 20% TruMove spray 01 of composition provided in Table- 1 below.
  • Table-2 Composition of 20% TruMove spray 01 1.3. Preparation of 20% TruMove spray 03
  • Table-3 Composition of 20% TruMove spray 03
  • a topical spray comprising not less than 20% w/w of beta-caryophyllene is evaluated for stability at 40 °C ⁇ 2 °C /75 ⁇ 5 % RH and 30 °C ⁇ 2 °C / 75 ⁇ 5 % RH for initial, 3 months’ and 6 months’ .
  • the result of the study is provided in Table-4 below:
  • a comparative study is performed to evaluate the analgesic efficiency of the composition disclosed herein in form of a spray comprising 20% w/w of P-caryophyllene (TruMove Spray) in comparison with a standard pain relief spray comprising 1 % w/w of Diclofenac sodium.
  • Table-5 WOMAC score
  • Table-6 McGill Pain score comparison.

Abstract

The present invention provides a topical spray composition based on the phytocannabinoid β- caryophyllene (BCP) for the management of pain, inflammation, and related disorders. The composition comprises β-caryophyllene in isolated form, benzalkonium chloride, propellant, pharmaceutically acceptable excipient, and optionally an additional active component. The topical spray composition has enhanced absorption on skin and imparts effective protection against pain, inflammation, and related disorders. The composition is specifically useful in the treatment of chronic inflammatory disorders as it is free from undesirable side-effects like psycho-activity, dependence, and sedation. The present invention also provides a method for producing the same and uses thereof.

Description

A TOPICAL SPRAY BASED ON BETA CARYOPHYLENE FOR THE
MANAGEMENT OF PAIN AND INFLAMMATION
FIELD OF THE INVENTION
The present invention generally relates to pharmaceutical sciences. Specifically, the present invention is related to a topical spray composition comprising isolated P-caryophyllene, benzalkonium chloride, propellant, pharmaceutically acceptable excipients, and optionally an additional active component for the management of pain, inflammation, and other pain related disorders. Also, the present invention provides a method for producing the same and uses thereof.
BACKGROUND OF THE INVENTION
Beta-Caryophyllene (P-Caryophyllene) chemically represented as trans-(lR, 9S)-8-Methylene- 4,l l,l l-trimethylbicyclo-7.2.0 undec-4-ene or lR-(lR4E.9S)-4,l l,l l-trimethyl-8-methylene- bicyclo7.2.0 undec-4-ene) is a natural bicyclic sesquiterpene compound found in spice blends, citrus flavors, Soaps, detergents, creams and lotions, and also in a variety of food products and beverages.
In nature, it mainly occurs as trans-caryophyllene ((E)-BCP) mixed with small amounts of its isomers, (Z)-P-caryophyllene (iso-caryophyllene) and a-humulene (a-caryophyllene), as well as its oxidation derivative — P-caryophyllene oxide (BCPO). In scientific literature, BCP mainly stands for (E)-BCP or the natural mixture of BCP isomers. P-caryophyllene is the first known dietary cannabinoid, a common component of food that has GRAS (Generally Recognized as Safe) status and approved by FDA as well as by the European Food Safety Authority (EFSA) with identification number FL no: 01.007 for food use.
BCP is a colorless to slightly buttery liquid with a light clove-like fragrance. It is soluble in ether and ethanol, insoluble in water. The chemical structure of P-caryophyllene is as follows:
Figure imgf000003_0001
BCP is one of the major active components of essential oils derived from large number of spice and food plants. According to Essential Oil Database, BCP as a plant volatile compound is commonly found in basil (Ocimum spp.), cinnamon (Cinnamomum spp.), black pepper (Piper nigrum L.), cloves (Syzygium aromaticum), cannabis (Cannabis sativa L.), lavender (Lavandula angustifolia), oregano (Origanum vulgare L.), rosemary (Rosmarinus officinalis), hops (Humulus lupulus), and copaiba (Copaifera langsdorffii).
P-caryophyllene has several biological effects including anti-inflammatory, anticarcinogenic, antimicrobial, antioxidative, and analgesic activities. P-caryophyllene is the primary sesquiterpene contributing to the spiciness of black pepper. P-caryophyllene belongs to a class of cannabinoids (CBs), specifically phytocannabinoids (pCBs), which were identified as plant derivatives of Cannabis sativa L.
Natural and synthetic cannabinoids activate the cannabinoid receptors CB1 and CB2, however P- caryophyllene activates exclusively CB2 and exhibits no affinity to CB1. Klaudyna et. al. [Cancer Medicine 2016; 5( 10):3007-3017] in a study reported through quantitative radioligand binding experiments that P-caryophyllene displays insensibly higher biding affinity to CB2 and do not bind to CB 1. This implies that P-caryophyllene action is devoid of psychoactive side effects associated with CB 1 activation and suggests its potential use in medicine.
This selective CB2 activation properties of P-caryophyllene suggests that P-caryophyllene has potential as natural analgesic through significant cannabimimetic anti-inflammatory effects. Further, Clayton et al. [Pain 96(2002) 253-260] in a study reported that activation of CB2 receptor alone is sufficient to produce anti-inflammatory and analgesic effect. Activation of CB 1 receptor is likely to produce unwanted CNS side effects as these receptors have a wide distribution in the brain and are associated with psychoactivity, dependence and sedation. There is no such reported side effect associated with CB2 agonists. CB2 receptors are expressed exclusively in peripheral tissues and are not associated with any side effects. CB2 agonists therefore have the potential to provide safe and effective treatment of chronic inflammatory disorders.
Pain is a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors — peripheral neurons responding to pain stimuli. Pain is classified as acute or chronic, according to its duration. Short-lived pain, generally associated with tissue damage or painful stimuli (e.g. the pain associated with a slight burn, a cut etc.), is defined "acute pain", and has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it.
On the other hand, pain which persists beyond the time necessary for resolution of an acute condition is defined as "chronic pain". Pain is a serious social burden; it affects quality of life and leads to economic loss for patients as well as health services. It has been estimated that 20% of adults suffer from pain globally and around 10% of population worldwide suffers from long lasting pain [Goldberg and McGee BMC Public Health 2011, 11:770].
In the treatment of pain, in particular chronic pain, various substances are used, generally of a synthetic nature such as non-steroid anti-inflammatory drugs, opioids, etc., which induce analgesia, i.e., reduction in the sensation of pain. The treatments may be necessary for long periods, sometimes even for life. This leads to overuse of synthetic or semisynthetic pain killers such as opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). Prolonged consumption of these medicines may cause serious side effects leading to health complications as well as drug tolerance for analgesic effect and addiction. To decrease use of synthetic drugs, natural products with strong analgesic activities and low side effects are sought. Because of these cannabinoid receptors have been extensively studied as mediators of analgesia and thus potential targets for treatment of acute and neuropathic pain and inflammation. Activation of those receptors by endo- and exogenous ligands may inhibit pain responses, therefore CBs are considered as substances with high analgesic activities. Highly studied natural product i.e., cannabinoids from cannabis majorly contains tetrahydrocannabinol (THC), which is approved for the supportive care of several medical conditions in Austria, Belgium, Canada, and several states of the United States. THC mediates through cannabinoid receptors CB 1 and CB2. Therefore, long term usage can lead to psychoactivity, dependence and sedation.
In view of the above findings, it is evident that P-caryophyllene has potential as an efficient natural analgesic without any side effects like psychoactivity, dependence and sedation. P-caryophyllene based analgesic compositions have been reported.
US20080280996 provides a composition comprising caryophyllenes including P-caryophyllene for the treatment of inflammatory conditions and inflammatory pain.
AU2020412501 provides a composition comprising terpenes including P-caryophyllene for the treatment of pain and anxiety.
However, P-caryophyllene has extremely low solubility in biological fluids leading to low bioavailability of P-caryophyllene and insufficient analgesic effect. This limits exploitation of this readily available, natural, and safe analgesic to its fullest potential.
Therefore, need exists for the development of a P-caryophyllene -based analgesic topical spray composition which has enhanced skin absorption and bioavailability of P-caryophyllene for faster and efficient pain relief without any side effects like sedation, addiction, and psychoactivity.
SUMMARY OF THE INVENTION Accordingly, the present invention provides a topical spray composition for the management of pain, inflammation, and related disorders. The said composition comprises 2% w/w to 98% w/w of an isolated P-caryophyllene, 0.01% w/w to 3.5% w/w of benzalkonium chloride, 10% w/w to 70% w/w of a propellant, 30% w/w to 70% w/w of at least one excipient, and optionally 0.05% w/w to 40% w/w of an additional active component.
The said composition is in form of a topical spray which can be sprayed on the skin to obtain relief from pain and inflammation within 2 minutes and the analgesic effect imparted by the said topical spray composition sustains for about 18 hours. The topical spray composition provided herein has enhanced absorption on the skin.
The present invention also provides simple process for the preparation of said topical spray composition, method for the management of pain, inflammation, and related disorders by spraying said composition on the skin of a subject, and uses of said composition in the management of pain, inflammation, and related disorders.
The topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
The topical spray composition provided herein has analgesic effect better than the standard diclofenac -based analgesic sprays and has no side-effects like psycho-activity, dependence, and sedation.
BRIEF DESCRIPTION OF DRAWINGS
The accompanying drawings illustrate some of the embodiments of the present invention and, together with the descriptions, serve to explain the invention. These drawings have been provided by way of illustration and not by way of limitation. The components in the drawings are not necessarily drawn to scale, emphasis instead being placed upon clearly illustrating the principles of the aspects of the embodiments. Figure 1 illustrates onset time through evaluation of response latency of the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
Figure 2 illustrates duration of analgesic effect through evaluation of % protection against acute pain imparted by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac ( 1 % w/w of Diclofenac sodium).
Figure 3 illustrates Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and McGill pain scores from baseline to Post study in both the groups by the composition disclosed herein (20% w/w of P-caryophyllene, TruMove Spray) in comparison with standard pain relief spray based on diclofenac (1% w/w of Diclofenac sodium).
DETAILED DESCRIPTION OF THE INVENTION
The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully interpreted and comprehended. However, any skilled person or artisan will appreciate the extent to which such embodiments could be generalized in practice.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of such compounds, and reference to "the step" includes reference to one or more steps and equivalents thereof known to those skilled in the art, and so forth.
The publications discussed herein are provided solely for their availability to the applicant before the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by the prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred method, and materials are now described.
The term “TruMove” or “TruMove spray” used herein refers to a series of test products based on the topical spray composition provided herein.
In one aspect of the present invention, there is provided a topical spray composition for the management of pain, inflammation, and related disorders comprising: a therapeutically effective amount of an isolated P-caryophyllene; a pharmaceutically acceptable amount of a benzalkonium chloride; a pharmaceutically acceptable amount of a propellant; a pharmaceutically acceptable excipient; and optionally an additional active component.
The term “P-caryophyllene" or “beta-caryophyllene” or “BCP” or “beta caryophyllene” used herein refers to a compound represented by the following formula:
Figure imgf000009_0001
and chemically defined as trans-(lR, 9S)-8-Methylene-4,l l,l l-trimethylbicyclo-7.2.0 undec-4- ene or 1R-(1R4E.9S)-4,11,1 l-trimethyl-8-methylene-bicyclo7.2.0 undec-4-ene).
The term “isolated P-caryophyllene” used herein refers to P-caryophyllene available commercially as mixture of oils, P-caryophyllene extracted from natural plants by conventional methods, or P- caryophyllene prepared by synthetic routes.
The topical spray composition provided herein comprises a therapeutically effective amount of isolated P-caryophyllene.
In an embodiment of the present invention, the topical spray composition provided herein comprises about 2% w/w to 98% w/w of isolated P-caryophyllene.
In an embodiment of the present invention, the isolated P-caryophyllene present in the topical spray composition is in form of oil comprising about 70% w/w to 100% w/w of P-caryophyllene.
In an embodiment of the present invention, the isolated P-caryophyllene present in the topical spray composition is in form of oil extracted from a group of plants comprising basil {Ocimum spp.), cinnamon {Cinnamomum spp.), black pepper Piper nigrum L.), cloves {Syzygium aromaticuni), cannabis Cannabis sativa L.), lavender {Lavandula angustifolia), oregano {Origanum vulgare L.), rosemary {Rosmarinus officinalis), hops {Humulus lupulus), and copaiba {Copaifera langsdorffii). In an embodiment of the present invention, the isolated P-caryophyllene is extracted from cloves.
In an embodiment of the present invention, the isolated P-caryophyllene is extracted from clove leaves. The term "therapeutically effective amount" as used herein refers to the amount of the active ingredient in a composition which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
The therapeutically effective amount of isolated P-caryophyllene in the topical spray composition disclosed herein is in a range of about 20mg to 980mg.
In an embodiment of the present invention, the therapeutically effective amount of isolated P- caryophyllene is in a range of about lOmg to 70mg. The term “about” used herein refers to the referenced numeric indication plus or minus 10% of that referenced numeric indication.
The term “Benzalkonium Chloride” or “BAC” used herein refers to a compound represented by the following formula:
Figure imgf000010_0001
wherein n is equal to 8, 10, 12, 14, 16 and 18. The topical spray composition provided herein comprises a pharmaceutically acceptable amount of benzalkonium chloride. In an embodiment of the present invention, the topical spray composition provided herein comprises benzalkonium chloride in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
The topical spray composition provided herein has enhanced skin absorption due to incorporation of benzalkonium chloride. The enhanced absorption of the composition disclosed herein is increasing the bioavailability of P-caryophyllene and enabling sufficient analgesic effect in highly safe manner through activation of only CB2 receptor.
The topical spray composition provided herein comprises a pharmaceutically acceptable excipient.
The term “pharmaceutically acceptable excipient” used herein refers to a compound or ingredient that is compatible with the other ingredients in a pharmaceutical composition and not injurious to an intended subject when administered in normal or therapeutically effective amounts. As used herein, an “intended subject” includes animals and/or humans. The terms “patient” and “subject” may be used interchangeably.
In an embodiment of the present invention, the topical spray composition provided herein comprises an excipient in a concentration range of 30% w/w to 70% w/w of the composition.
In an embodiment of the present invention, the topical spray composition provided herein comprises an excipient selected from a group of commonly used excipients in topical spray compositions comprising emulsifier, preservative, penetration enhancer, emollient, stabilizing agent, solvent, fragrance, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable emulsifier selected from a group of commonly used emulsifiers comprising non-ionic surface active agent e.g., polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, anionic surface active agent e.g., alkyl phosphoric acid ester, alkyl sulfate ester, soap, polyoxyethylene alkyl phosphate acid ester, polyoxyethylene alkyl sulfate, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable stabilizing agent selected from a group of commonly used stabilizing agents comprising sodium alginate, sodium carboxymethyl cellulose (CMC), guar gum, locust bean gum, carrageenan, gelatin, pectin, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable preservative selected from a group of commonly used preservatives comprising benzalkonium chloride, diazolidinyl urea; iodopropnyl butylcarbamate; vitamin E (alpha- tocopherol) and its derivatives including vitamin E acetate (alpha-tocopherol acetate); vitamin C (ascorbic acid); butylated hydroxytoluene (BHT); butylated hydroxyanisole (BHA); esters of p-hydroxy benzoic acid such as methylparaben (p-hydroxybenzoic acid methyl ester), ethylparaben (p- hydroxybenzoic acid ethyl ester), propylparaben (p-hydroxybenzoic acid n- propyl ester), and butylparaben (p-hydroxybenzoic acid n-butyl ester), and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable emollient selected from a group of commonly used emollients comprising oils, waxes, natural oils derived from plants, silicone oil, polyunsaturated fatty acid, lanoline, dicaprylic ether, isopropyl palmitate, dicaprylyl carbonate, C12-C15 alkyl benzoate, isopropyl isononate, sucrose palmitate, sucrose oleate, isostearyl lactate, glyceryl behenate, triglycerol-4 isostearate, lauryl pirrolidone carboxylic acid, pantenyl triacetate, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable solvent selected from a group of commonly used solvents comprising ketones such as acetone, diacetone alcohol, dihydroxyacetone, ethyl butyl Valero lactone, methyl ethyl ketone etc., aliphatic or aromatic alcohols such as methanol, ethanol, propanol, benzyl alcohol, butyl alcohol, t-butyl alcohol, butylene glycol, diethylene glycol, abietyl alcohol, propylene carbonate, hexyl alcohol, isopropanol etc., glycol ethers such as butoxy ethanol, butoxypropanol, 3-methyl-3-methoxy-butanol, methoxypropanol etc., esters such as butyl acetate, ethyl acetate, 1 -methoxy-2-propanol acetate etc., benzoates, siloxanes, cyclic silicones, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises ethanol as solvent.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable fragrance or flavouring agent selected from a group of commonly used fragrances or flavouring agents selected from a group comprising natural oils, synthetic oils, alcohols, aldehydes, ketones, esters, lactones, hydrocarbons, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a pharmaceutically acceptable penetration enhancer selected from a group comprising pyrrolidone, alcohol especially, ester, water, ester sulfoxide (such as dimethyl sulfoxide) and their derivatives, hydrocarbon, terpene and derivatives, benzalkonium chloride, azone and its analogs, amide (including urea and its derivatives), fatty acids, surfactants, oleodendrimers, ionic liquids, and deep eutectic solvents, and a combination thereof.
The topical spray composition provided herein comprises a propellant.
The propellant used in the topical spray provided herein can be any pharmaceutically acceptable propellant which provides a suitable pressure within an aerosol dispenser, preferably a pressure in range of 20 pounds per square inch gauge (psig) to 130 pounds per square inch gauge (psig).
In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant in a concentration range of 10% w/w to 70% w/w of the composition. In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant selected from a group comprising nitrogen, carbon dioxide, hydrocarbons, and a combination thereof.
In an embodiment of the present invention, the topical spray composition provided herein comprises a propellant selected from a group comprising LPG, propane, butane, isobutane, dimethylether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
The topical spray composition provided herein comprises an optional additional active component.
The term “active component” used herein refers to a component which has some already known biological activity. The said component can be an individual biologically active compound or a mixture of biologically active compounds. The biologically active compounds may or may not have analgesic activity. The said component can be of natural origin, a natural identical of a natural compound, or a semi-synthetic derivative of a natural compound.
In an embodiment of the present invention, the topical spray composition provided herein comprises optionally an additional active component in a concentration range of 0.05% w/w to 40% w/w of the composition.
In an embodiment of the present invention, the topical spray composition provided herein comprises optionally an additional active component selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
The topical spray composition provided herein is applied topically on the skin once a day to four times a day to a patient or subject. The topical spray composition provided herein has an onset time between 2 minutes to 15 minutes.
The term "onset time" as used herein refers to the period of time between the topical application of the topical dosage form comprising the composition of the present invention and the release of the active ingredient thereof.
The topical spray composition provided herein has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
The topical spray composition provided herein is used for the management of pain, inflammation, and related disorders.
As used herein, the term “pain” or “inflammation" refers to a subjective sensation, evoked by various internal and external stimuli. It is an unpleasant feeling, which arises from sensitization of nociceptors, the peripheral neurons responding to pain stimuli. The term "pain” or “inflammation includes acute pain or inflammation as well as chronic pain or inflammation. The short-lived acute pain or inflammation is generally associated with tissue damage or painful stimuli (e.g., the pain associated with a slight burn, a cut etc.). Acute pain or inflammation has an adaptive value as it warns us of the presence and location of a lesion and allows us to correct the behavior which causes it or contributes to it. On the other hand, pain or inflammation which persists beyond the time necessary for resolution of an acute condition is defined as chronic pain or inflammation.
In an embodiment of the present invention, the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising arthralgia, backache, neuralgia, ischialgia, fibromyalgia, musculo-skeletal pain, pelvic pain, and related disorders.
In an embodiment of the present invention, the topical spray composition provided herein is useful in the management of pain in medical conditions selected from a group comprising atopic dermatitis, contact dermatitis, allergic dermatitis, pruritic dermatitis, solar (UVB -induced) dermatitis, chemical-induced dermatitis, bacterial and viral skin inflammation, acne, psoriasis, and related disorders.
In another aspect of the present invention, a process for the preparation of topical spray composition provided herein is disclosed. The said process comprises steps of, preparing a mixture of Mentha arvensis crystals and a solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture; adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture; adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture; preparing a solution of benzalkonium chloride in a solvent, adding the solution into the third mixture and stirring the third mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fourth mixture; diluting the fourth mixture with solvent and stirring the fourth mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fifth mixture; filtering the fifth mixture and filling the fifth mixture in a spray bottle with a propellant to obtain the composition.
The topical spray composition provided herein may be filled in an aluminium aerosol container without a propellant to obtain a topical spray.
In one of the embodiments of the present invention, the process for preparation of topical spray composition disclosed herein, ethanol is used as solvent.
In another aspect of the present invention, there is provided a method for the management of pain, inflammation, and related disorders by applying on the skin of a subject the topical spray composition provided by the present invention. In another aspect of the present invention, there is provided use of the topical spray composition provided by the present invention in the management of pain, inflammation, and related disorders.
The topical spray composition provided herein is natural, safe, economic, and easy to prepare on industrial scale.
The topical spray composition provided herein has analgesic effect better than diclofenac based topical analgesic sprays. Due to presence of natural analgesic P-caryophyllene as major component, the topical spray composition provided herein is extremely safe and free from adverse reactions like application site dermatitis which is generally experienced by patients in long term usage of diclofenac based topical sprays. The safety associated with the topical spray composition provided herein will lead to better patient compliance.
The topical spray composition provided herein has no side-effects like psycho-activity, dependence, sedation etc., and can be advantageously used as a safe alternative to natural cannabinoid analgesic e.g., THC which activates both CB1 and CB2 receptors to trigger undesirable psychoactivity.
It will be understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the present invention will suggest themselves to those skilled in the art. Other embodiments can be practiced that are also within the scope of the present invention. The following examples illustrate the invention, but by no means intended to limit the scope of the claims.
EXAMPLES
EXAMPLE 1: PREPARATION OF ANALGESIC SPRAY FTRUMOVE SPRAY1
1.1. Preparation of 20% TruMove spray 01
In main manufacturing vessel, a mixture of Mentha arvensis crystals and ethanol is prepared by stirring Mentha arvensis crystals and ethanol at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 20 minutes. In the mixture so obtained, Lavang (Syzygium aromaticum), Gandhapura (Gaultheria fragrantissima) Lf. Oil, Lavang (Syzygium aromaticum) Fl. Bud Oil, Sarala (Pinus roxburghii) Ht.Wd. Oil, Nilgiri (Eucalyptus globulus) Lf. Oil, and Dalchini (Cinnamomum zeylanicum) Dr. Inner Bk. Oil are added and stirred at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes. Thereafter, isopropyl myristate and polysorbate 80 (Tween 80) are added into the mixture so obtained followed by stirring at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes. An ethanolic solution of benzalkonium chloride is prepared in a separate container by stirring ethanol and benzalkonium chloride at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes. The ethanolic solution of benzalkonium chloride so prepared is then added into the mixture in main manufacturing vessel and stirred for 5 minutes at a speed in range of 10 rpm to 500 rpm. The mixture so obtained is then diluted with ethanol, stirred, and filtered to obtain a concentrate. The concentrate is then filled inside a spray bottle with a propellant to obtain 20% TruMove spray 01 of composition provided in Table- 1 below.
Table- 1: Composition of 20% TruMove spray 01
Figure imgf000018_0001
1.2.Preparation of 20% TruMove spray 02
20% TruMove spray 02 having composition as provided in Table-2 below is prepared using method detailed in Example 1.1.
Table-2: Composition of 20% TruMove spray 01
Figure imgf000018_0002
1.3. Preparation of 20% TruMove spray 03
20% TruMove spray 03 having composition as provided in Table-3 below is prepared using method detailed in Example 1.1.
Table-3: Composition of 20% TruMove spray 03
Figure imgf000019_0001
EXAMPLE 2: STABILITY STUDIES
A topical spray comprising not less than 20% w/w of beta-caryophyllene is evaluated for stability at 40 °C ± 2 °C /75 ± 5 % RH and 30 °C ± 2 °C / 75 ± 5 % RH for initial, 3 months’ and 6 months’ . The result of the study is provided in Table-4 below:
Table-4: Stability studies results
Figure imgf000019_0002
Conclusion: All the physical and chemical parameters of the spray are found satisfactory and the initial, 3M and 6M stability data at 40 °C ± 2 °C /75 ± 5 % RH, 30 °C ± 2 °C / 75 ± 5 % RH are also found to be satisfactory.
EXAMPLE 3: ANALGESIC EFFECT EVALUATION [TRUMOVE SPRAY]
A comparative study is performed to evaluate the analgesic efficiency of the composition disclosed herein in form of a spray comprising 20% w/w of P-caryophyllene (TruMove Spray) in comparison with a standard pain relief spray comprising 1 % w/w of Diclofenac sodium.
10 healthy male Wistar rats aged between 10 weeks to 12 weeks and weighing between 220 grams to 250 grams are divided into two groups of 5 animals. TruMove spray and the standard pain relief spray were measured in Eppendorf tube by spraying twice and mist volume of both sprays are found to be 500pl. Volume is kept same for all the rats. The response in the form of jumping, withdrawal of the paws or the licking of the paws is observed and response latency recorded by a stopwatch after 0, 30, 60, 90 and 120 mins of drug administration for all groups.
The study shows that there is significantly fast onset of action with Trumove spray (45 seconds) when compared to standard pain relief spray (56 seconds) in all the Musculo-skeletal pain conditions like low back ache, knee joint pain and other joint pain disorders. Also, the onset of pain relief is also fast (2.13 minutes) with Trumove spray when compared to standard pain relief spray (5.27 minutes) as illustrated in Figure- 1. The pain relief action sustains for around 18 hours in Trumove spray and for around 15 hours in standard pain relief spray as illustrated in Figure-2. Further, the VAS, WOMAC and McGill pain scores from baseline to Post study in Trumove spray and standard pain relief spray are comparable as reflected in Table-5 and Table-6 below and illustrated in Figure 3.
Table-5: WOMAC score
Figure imgf000020_0001
Table-6: McGill Pain score comparison.
Figure imgf000021_0001
The study also reflects that there is significant reduction in the inflammatory biomarkers ESR and Hs-CRP from baseline to Post study in both the groups, but ESR reduction is more prominent in Trumove spray group as reflected in Table-7 and Table-8 below. Table-7: ESR reduction
Figure imgf000021_0002
Table-8: Hs-CRP reduction
Figure imgf000021_0003
Conclusion: Pain relief is faster and better in TruMove spray than standard pain relief spray. It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained, and since certain changes may be made in the constructions set forth without departing from the spirit and scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense. The invention has been described with reference to preferred and alternate embodiments. Modifications and alterations will become apparent to those skilled in the art upon reading and understanding the detailed discussion of the invention provided herein. This invention is intended to include all such modifications and alterations insofar as they come within the scope of the present invention. These and other modifications of the preferred embodiments as well as other embodiments of the invention will be obvious from the disclosure herein, whereby the foregoing descriptive matter is to be interpreted merely as illustrative of the invention and not as a limitation.
Finally, to the extent necessary to understand or complete the disclosure of the present invention, all publications, patents, and patent applications mentioned herein are expressly incorporated by reference therein to the same extent as though each were individually so incorporated.

Claims

We claim:
1. A topical spray composition for the management of pain, inflammation, and related disorders comprising:
- a therapeutically effective amount of an isolated P-caryophyllene,
- a pharmaceutically acceptable amount of a benzalkonium chloride,
- a pharmaceutically acceptable amount of a propellant,
- a pharmaceutically acceptable excipient, and optionally an additional active component.
2. The composition as claimed in claim 1 , wherein the isolated P-caryophyllene is in form of an oil comprising P-caryophyllene.
3. The composition as claimed in claim 2, wherein the oil comprises 70% w/w to 100% w/w of the P-caryophyllene.
4. The composition as claimed in claim 1, wherein the isolated P-caryophyllene is in a concentration range of 2% w/w to 98% w/w of the composition.
5. The composition as claimed in claim 1, wherein the benzalkonium chloride is in a concentration range of 0.01% w/w to 3.5% w/w of the composition.
6. The composition as claimed in claim 1 , wherein the propellant is in a concentration range of 10% w/w to 70% w/w of the composition.
7. The composition as claimed in claim 1, wherein the excipient is in a concentration range of 30% w/w to 70% w/w of the composition.
8. The composition as claimed in claim 1, wherein the additional active component is in a concentration range of 0.05% w/w to 40% w/w of the composition.
9. The composition as claimed in claim 1, wherein the excipient is selected from a group comprising emulsifier, preservative, emollient, stabilizing agent, solvent, fragrance, penetration enhancer, and a combination thereof.
10. The composition as claimed in claim 1, wherein the additional active component is selected from a group comprising Gaultheria fragrantissima leaf oil, Mentha arvensis crystals, Syzygium aromaticum flower bud oil, Syzygium aromaticum (Lavang), Standaradized clove extract (containing P Caryophyllene), Pinus roxburghii heart wood oil, Eucalyptus globulus leaf oil, Cinnamomum zeylanicum dried inner bark oil, capsicum annuum, capsaicin, and a combination thereof.
11. The composition as claimed in claim 1 , wherein the propellant is selected from a group comprising liquified petroleum gas, propane, butane, isobutane, dimethyl ether, hydrofluorocarbons, hydrochlorofluorocarbons, nitrogen, air, and a combination thereof.
12. The composition as claimed in claim 1, wherein the composition is sprayed on the skin of the patient once a day to four times a day.
13. The composition as claimed in claim 1, wherein the composition has an onset time from 2 minutes to 15 minutes.
14. The composition as claimed in claim 1, wherein the composition has analgesic effect for a duration of 17 hours to 18 hours from the onset time.
15. A process for the preparation of composition as claimed in claim 1, wherein the process comprises step of:
- preparing a mixture of Mentha arvensis crystals and solvent in a mixer by stirring Mentha arvensis crystals and a solvent at a speed in range of 10 rpm to 500 rpm for a duration of 15 minutes to 25 minutes to obtain a first mixture;
- adding isolated P-caryophyllene, at least one excipient, and at least one additional active component into the first mixture and stirring the first mixture at a speed in range of 10 rpm to 500 rpm for a duration of 10 minutes to 15 minutes to obtain a second mixture;
- adding isopropyl myristate and polysorbate 80 (Tween 80) into the second mixture and stirring the second mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a third mixture; - preparing a solution of benzalkonium chloride in a solvent, adding the solution into the third mixture and stirring the third mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fourth mixture;
- diluting the fourth mixture with a solvent and stirring the fourth mixture at a speed in range of 10 rpm to 500 rpm for a duration of 5 minutes to 10 minutes to obtain a fifth mixture;
- filtering the fifth mixture and filling the fifth mixture in a spray bottle with a propellant to obtain the composition. A process as claimed in claim 15, wherein the solvent is ethanol. A method for the management of pain, inflammation, and related disorders in a subject by applying on the skin of the subject the composition as claimed in claim 1. Use of composition as claimed in claim 1 in the management of pain, inflammation, and related disorders.
PCT/IN2023/050741 2022-08-01 2023-08-01 A topical spray based on beta caryophylene for the management of pain and inflammation WO2024028896A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202211043958 2022-08-01
IN202211043958 2022-08-01

Publications (1)

Publication Number Publication Date
WO2024028896A1 true WO2024028896A1 (en) 2024-02-08

Family

ID=89848611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2023/050741 WO2024028896A1 (en) 2022-08-01 2023-08-01 A topical spray based on beta caryophylene for the management of pain and inflammation

Country Status (1)

Country Link
WO (1) WO2024028896A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
CN108420789A (en) * 2018-04-16 2018-08-21 海南皇隆制药股份有限公司 A kind of benzalkonium chloride externally used solution and preparation method thereof
US20200030252A1 (en) * 2018-07-18 2020-01-30 John Enrique Mata Multifunctional topical cream comprising beta-caryophyllene, essential oils, in a phospholipid and triglyceride base

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
CN108420789A (en) * 2018-04-16 2018-08-21 海南皇隆制药股份有限公司 A kind of benzalkonium chloride externally used solution and preparation method thereof
US20200030252A1 (en) * 2018-07-18 2020-01-30 John Enrique Mata Multifunctional topical cream comprising beta-caryophyllene, essential oils, in a phospholipid and triglyceride base

Similar Documents

Publication Publication Date Title
US10206888B2 (en) Cannabis-based therapeutic product for treatment of chronic pain
US10172897B2 (en) Enhanced smokable therapeutic cannabis product and method for making same
Jablonsky et al. Valorisation of softwood bark through extraction of utilizable chemicals. A review
US20180352848A1 (en) Smokable cannabis-based product with reduced psychoactive effects
WO2018226899A1 (en) A system and method enhanced cannabinoid effect delivery
US20210330638A1 (en) Nano-penetrative cannabinoid oil blends and compositions and methods of formulation thereof
US20190275268A1 (en) Multi-use cartridge for ingestion of cannabis-based products
US20180344684A1 (en) Cannabis-based therapeutic product for treatment of sleep disorders
US9040103B2 (en) Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses
US20200237714A1 (en) Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof
Avoseh et al. Albizia lebbeck and Albizia zygia volatile oils exhibit anti-nociceptive and anti-inflammatory properties in pain models
US20190321306A1 (en) Cannabis-based therapeutic product for treatment of chronic pain
WO2020234650A1 (en) Pharmaceutical compositions comprising cbd and terpene compositions
Adedoyin et al. Cytotoxicity, antioxidant and antimicrobial activities of essential oil extracted from Euphorbia heterophylla plant
Thakur et al. Therapeutic potential of essential oil-based microemulsions: reviewing state-of-the-art
US20220226241A1 (en) Stable organic cannabinoid oil blend formulations
WO2019173242A1 (en) Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
Qneibi et al. A comprehensive review of essential oils and their pharmacological activities in neurological disorders: Exploring neuroprotective potential
WO2024028896A1 (en) A topical spray based on beta caryophylene for the management of pain and inflammation
Jamzadfard et al. Improvement of the anxiety and depression during using Camaneur herbal distilate: comperhensive survey of the antioxidant effects
US11007243B2 (en) Enzyme-assisted supercritical extraction of nigella sativa seeds
US20200094003A1 (en) Multi-use cartridge for ingestion of cannabis-based products
WO2024028897A1 (en) A topical composition based on beta caryophylene for the management of pain and inflammation
US20220304963A1 (en) Composition having an optimized fatty acid excipient profile
Al-Harrasi et al. Essential Oil Chemistry vs. Aromatherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23849663

Country of ref document: EP

Kind code of ref document: A1